Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...

Lumicera Health Services announced today it has secured a purchase agreement with Anda, Inc., an independent wholly owned subsidiary of Teva Pharmaceutical Industries Ltd., for a lower-priced ...

SmithRx, a transparent, 100% pass-through modern pharmacy benefits manager (PBM), today announced a major expansion to its Connect 360 Autoimmune Prog ...

In addition to the introduction of the Stelara biosimilar ... which has been instrumental in sourcing the lowest priced prescription options for SmithRx’s members – SmithRx is partnering ...

Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...

The FDA had approved Otulfi in September 2024 to treat Crohn’s disease, ulcerative colitis, psoriasis and active psoriatic arthritis. Information on pricing is not yet available.

Celltrion launches Steqeyma autoimmune treatment in U.S. market Celltrion unveils its competitive approach for Steqeyma in ...